By REBECCA DYER A false-color scanning electron microscope image of a fibrin blood clot before and after the buildup of protofibrils. (Anurag Sharma/Pradeep Singh)Lecanemab received FDA approval in January after a phase 3 trial showed it slows cognitive decline in early-stage Alzheimer’s patients. While we know lecanemab clears amyloid beta buildup, it was unclear how...
by The Mount Sinai Hospital Credit: CC0 Public Domain Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no FDA-approved treatments specifically targeting this disorder. But a new study, published in the New England Journal of Medicine, suggests that patients experiencing the...
by Indiana University School of Medicine Credit: Pixabay/CC0 Public Domain Indiana University School of Medicine researchers have found that niacin limits Alzheimer’s disease progression when used in models in the lab, a discovery that could potentially pave the way toward therapeutic approaches to the disease. The study, recently published in Science Translational Medicine, investigates how...
Researchers first to report neuroprotective properties of granulocyte colony-stimulating factor FLORIDA ATLANTIC UNIVERSITY Stroke is the third leading cause of death and disability in the United States. More than 87 percent are ischemic strokes, caused by obstruction of one or more cerebral arteries. With limited progress in developing treatments, there is a critical need for...
